Anne-Brita Knapskog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne-Brita Knapskog has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Ingvild Saltvedt
Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
7 shared publications - Halvor Naess
Department of Neurology, Haukeland University Hospital, Bergen, Norway
5 shared publications Knut Engedal
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway
5 shared publications- Torunn Askim
Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Science, NTNU-Norwegian University of Science and Technology, Trondheim, Norway
5 shared publications - Geir Selbæk
Norwegian National Centre for Ageing and Health Vestfold Hospital Trust Tønsberg Norway
4 shared publications - Katinka Nordheim Alme
Institute of Clinical Medicine (K1), University of Bergen, Bergen, Norway
4 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 14 May 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (5) , 1079-1102
Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology
ULK1 (Atg1) initiates macroautophagy and mitophagy, which support neuronal growth and survival, yet how this pathway is disrupted in aging and Alzheimer's disease (AD) remains unclear. Here we report reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316). In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality. Mechanistically, ULK1 upregulation increases autophagy and PINK1-, FUNDC1- and AMBRA1-associated mitophagy; higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy. We propose that age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD and identify ULK1 as a potential therapeutic target.
- 14 May 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (5) , 1079-1102
Top Cited PapersOpen AccessReduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology
ULK1 (Atg1) initiates macroautophagy and mitophagy, which support neuronal growth and survival, yet how this pathway is disrupted in aging and Alzheimer's disease (AD) remains unclear. Here we report reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316). In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality. Mechanistically, ULK1 upregulation increases autophagy and PINK1-, FUNDC1- and AMBRA1-associated mitophagy; higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy. We propose that age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD and identify ULK1 as a potential therapeutic target.
- Open Access
- 7 May 2026
- Published by Springer Nature in European Review of Aging and Physical Activity
- Vol. 23 (1)
Changes in device-measured daily physical activity over one year in memory clinic patients
Background: This longitudinal study explored the one-year change in device-measured daily physical activity in patients attending a memory clinic. Methods: Physical activity was recorded in 27 memory clinic patients over four days using accelerometers (activPAL3 micro) at baseline and one-year follow-up. Daily physical activity outcomes included upright time, standing time, walking time, number of steps, number of transitions, mean upright event length, and maximum upright event length. Changes between baseline and follow-up were analysed using paired sample t-tests. Results: Patients’ mean (SD) age was 69.4 (8.1) years, and 14 (51.9%) were women. The only significant change was a decrease in maximum upright event length from a mean (SD) of 84.3 (31.6) minutes at baseline to 59.2 (22.5) minutes at one-year follow-up ( p < 0.001). Conclusion: Daily physical activity volume remained stable over one year, but the reduction in maximum upright event length indicates a shift in activity distribution.
- 7 May 2026
- Published by Springer Nature in European Review of Aging and Physical Activity
- Vol. 23 (1)
Open AccessChanges in device-measured daily physical activity over one year in memory clinic patients
Background: This longitudinal study explored the one-year change in device-measured daily physical activity in patients attending a memory clinic. Methods: Physical activity was recorded in 27 memory clinic patients over four days using accelerometers (activPAL3 micro) at baseline and one-year follow-up. Daily physical activity outcomes included upright time, standing time, walking time, number of steps, number of transitions, mean upright event length, and maximum upright event length. Changes between baseline and follow-up were analysed using paired sample t-tests. Results: Patients’ mean (SD) age was 69.4 (8.1) years, and 14 (51.9%) were women. The only significant change was a decrease in maximum upright event length from a mean (SD) of 84.3 (31.6) minutes at baseline to 59.2 (22.5) minutes at one-year follow-up ( p < 0.001). Conclusion: Daily physical activity volume remained stable over one year, but the reduction in maximum upright event length indicates a shift in activity distribution.
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e101515
Associations between neurodegenerative and acute injury biomarkers and post‐stroke cognitive impairment – the Nor‐COAST study
Background: Patients with vascular risk factors have a higher incidence of Alzheimer's disease (AD), and AD patients have an increased risk of experiencing stroke. About half of all stroke survivors experience post‐stroke cognitive impairment (PSCI). Stroke triggers numerous inflammatory and neurodegenerative processes both in the acute and chronic phases. The aims of this study were to investigate longitudinal plasma biomarker data in a stroke population and whether high levels of neurodegenerative and acute injury biomarkers at baseline could predict PSCI. Method: In this Nor‐COAST substudy, we included 547 stroke patients (Age [mean = 73± 12], 56 % males, 89 % ischemic strokes, 11 % haemorrhagic strokes). Brain‐derived tau (BD‐tau), phosphorylated tau 181 ( p ‐tau 181 ), total tau (t‐tau), amyloid β40 (Aβ 40 ), Aβ 42 , glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) concentrations were measured on the Simoa platform in plasma samples collected at inclusion, and after 3, 18 and 36 months. We explored the biomarkers’ associations with cognitive decline as measured by the Montreal Cognitive Assessment (MoCA) scale up to 36 months post‐stroke. Result: Within the first three months BD‐tau, t‐tau, and GFAP concentrations declined by 43%, 20% and 76% respectively, whereas NfL levels continued to decrease up to 18 months (59%). p ‐tau 181 increased gradually by 24 % from acute phase to 36 months. Aβ 42 remained unchanged. Higher acute phase concentrations of BD‐tau, NfL and p ‐tau 181 predicted lover MoCA score up to 36 months post‐stroke in patients with ischemic stroke ( p value < 0.05). However, including clinical parameters attenuated the associations. These associations were not found in the patients with haemorrhagic stroke. Conclusion: Concentrations of plasma BD‐tau, NfL, GFAP, and t‐tau were increased in the acute phase of stroke, but no significant change was seen for Aβ 42 . BD‐tau, t‐tau and GFAP concentrations decreased to stable levels within 3 months of event, NfL stabilized within 18 months, whereas p ‐tau181 showed an increase. Higher concentrations of BD‐tau, NfL, and p ‐tau 181 were associated with worse cognitive outcome up to 36 months post‐stroke. These results indicate that stroke trigger a continuing neurodegenerative process, as demonstrated by gradually increasing concentrations of p ‐tau 181 leading to PSCI.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e101515
Open AccessAssociations between neurodegenerative and acute injury biomarkers and post‐stroke cognitive impairment – the Nor‐COAST study
Background: Patients with vascular risk factors have a higher incidence of Alzheimer's disease (AD), and AD patients have an increased risk of experiencing stroke. About half of all stroke survivors experience post‐stroke cognitive impairment (PSCI). Stroke triggers numerous inflammatory and neurodegenerative processes both in the acute and chronic phases. The aims of this study were to investigate longitudinal plasma biomarker data in a stroke population and whether high levels of neurodegenerative and acute injury biomarkers at baseline could predict PSCI. Method: In this Nor‐COAST substudy, we included 547 stroke patients (Age [mean = 73± 12], 56 % males, 89 % ischemic strokes, 11 % haemorrhagic strokes). Brain‐derived tau (BD‐tau), phosphorylated tau 181 ( p ‐tau 181 ), total tau (t‐tau), amyloid β40 (Aβ 40 ), Aβ 42 , glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) concentrations were measured on the Simoa platform in plasma samples collected at inclusion, and after 3, 18 and 36 months. We explored the biomarkers’ associations with cognitive decline as measured by the Montreal Cognitive Assessment (MoCA) scale up to 36 months post‐stroke. Result: Within the first three months BD‐tau, t‐tau, and GFAP concentrations declined by 43%, 20% and 76% respectively, whereas NfL levels continued to decrease up to 18 months (59%). p ‐tau 181 increased gradually by 24 % from acute phase to 36 months. Aβ 42 remained unchanged. Higher acute phase concentrations of BD‐tau, NfL and p ‐tau 181 predicted lover MoCA score up to 36 months post‐stroke in patients with ischemic stroke ( p value < 0.05). However, including clinical parameters attenuated the associations. These associations were not found in the patients with haemorrhagic stroke. Conclusion: Concentrations of plasma BD‐tau, NfL, GFAP, and t‐tau were increased in the acute phase of stroke, but no significant change was seen for Aβ 42 . BD‐tau, t‐tau and GFAP concentrations decreased to stable levels within 3 months of event, NfL stabilized within 18 months, whereas p ‐tau181 showed an increase. Higher concentrations of BD‐tau, NfL, and p ‐tau 181 were associated with worse cognitive outcome up to 36 months post‐stroke. These results indicate that stroke trigger a continuing neurodegenerative process, as demonstrated by gradually increasing concentrations of p ‐tau 181 leading to PSCI.
- Open Access
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1303-1311
Plasma Inflammatory Biomarkers Are Associated With Poststroke Cognitive Impairment: The Nor-COAST Study
Background: Inflammation is proposed to be involved in the pathogenesis of poststroke cognitive impairment. The aim of this study was to investigate associations between concentrations of systemic inflammatory biomarkers after ischemic stroke and poststroke cognitive impairment. Methods: The Nor-COAST study (Norwegian Cognitive Impairment After Stroke) is a prospective observational multicenter cohort study, including patients hospitalized with acute stroke between 2015 and 2017. Inflammatory biomarkers, including the TCC (terminal C5b-9 complement complex) and 20 cytokines, were analyzed in plasma, collected at baseline, 3-, and 18 months poststroke, using ELISA and a multiplex assay. Global cognitive outcome was assessed with the Montreal Cognitive Assessment (MoCA) scale. We investigated the associations between plasma inflammatory biomarkers at baseline and MoCA score at 3-, 18-, and 36-month follow-ups; the associations between inflammatory biomarkers at 3 months and MoCA score at 18- and 36-month follow-ups; and the association between these biomarkers at 18 months and MoCA score at 36-month follow-up. We used mixed linear regression adjusted for age and sex. Results: We included 455 survivors of ischemic stroke. Higher concentrations of 7 baseline biomarkers were significantly associated with lower MoCA score at 36 months; TCC, IL (interleukin)-6, and MIP (macrophage inflammatory protein)-1α were associated with MoCA at 3, 18, and 36 months ( P P P <0.01). Conclusions: Higher concentrations of plasma inflammatory biomarkers were associated with lower MoCA scores up to 36 months poststroke. This was most pronounced for inflammatory biomarkers measured in the acute phase following stroke. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02650531.
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1303-1311
Open AccessPlasma Inflammatory Biomarkers Are Associated With Poststroke Cognitive Impairment: The Nor-COAST Study
Background: Inflammation is proposed to be involved in the pathogenesis of poststroke cognitive impairment. The aim of this study was to investigate associations between concentrations of systemic inflammatory biomarkers after ischemic stroke and poststroke cognitive impairment. Methods: The Nor-COAST study (Norwegian Cognitive Impairment After Stroke) is a prospective observational multicenter cohort study, including patients hospitalized with acute stroke between 2015 and 2017. Inflammatory biomarkers, including the TCC (terminal C5b-9 complement complex) and 20 cytokines, were analyzed in plasma, collected at baseline, 3-, and 18 months poststroke, using ELISA and a multiplex assay. Global cognitive outcome was assessed with the Montreal Cognitive Assessment (MoCA) scale. We investigated the associations between plasma inflammatory biomarkers at baseline and MoCA score at 3-, 18-, and 36-month follow-ups; the associations between inflammatory biomarkers at 3 months and MoCA score at 18- and 36-month follow-ups; and the association between these biomarkers at 18 months and MoCA score at 36-month follow-up. We used mixed linear regression adjusted for age and sex. Results: We included 455 survivors of ischemic stroke. Higher concentrations of 7 baseline biomarkers were significantly associated with lower MoCA score at 36 months; TCC, IL (interleukin)-6, and MIP (macrophage inflammatory protein)-1α were associated with MoCA at 3, 18, and 36 months ( P P P <0.01). Conclusions: Higher concentrations of plasma inflammatory biomarkers were associated with lower MoCA scores up to 36 months poststroke. This was most pronounced for inflammatory biomarkers measured in the acute phase following stroke. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02650531.
- Open Access
- 17 January 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (2)
Cerebrospinal fluid quinolinic acid is strongly associated with delirium and mortality in hip-fracture patients
BACKGROUND. The kynurenine pathway (KP) has been identified as a potential mediator linking acute illness to cognitive dysfunction by generating neuroactive metabolites in response to inflammation. Delirium (acute confusion) is a common complication of acute illness and is associated with increased risk of dementia and mortality. However, the molecular mechanisms underlying delirium, particularly in relation to the KP, remain elusive. METHODS. We undertook a multicenter observational study with 586 hospitalized patients (248 with delirium) and investigated associations between delirium and KP metabolites measured in cerebrospinal fluid (CSF) and serum by targeted metabolomics. We also explored associations between KP metabolites and markers of neuronal damage and 1-year mortality. RESULTS. In delirium, we found concentrations of the neurotoxic metabolite quinolinic acid in CSF (CSF-QA) (OR 2.26 [1.78, 2.87], P < 0.001) to be increased and also found increases in several other KP metabolites in serum and CSF. In addition, CSF-QA was associated with the neuronal damage marker neurofilament light chain (NfL) (β 0.43, P < 0.001) and was a strong predictor of 1-year mortality (HR 4.35 [2.93, 6.45] for CSF-QA ≥ 100 nmol/L, P < 0.001). The associations between CSF-QA and delirium, neuronal damage, and mortality remained highly significant following adjustment for confounders and multiple comparisons. CONCLUSION. Our data identified how systemic inflammation, neurotoxicity, and delirium are strongly linked via the KP and should inform future delirium prevention and treatment clinical trials that target enzymes of the KP. FUNDING. Norwegian Health Association and South-Eastern Norway Regional Health Authorities.
- 17 January 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (2)
Open AccessCerebrospinal fluid quinolinic acid is strongly associated with delirium and mortality in hip-fracture patients
BACKGROUND. The kynurenine pathway (KP) has been identified as a potential mediator linking acute illness to cognitive dysfunction by generating neuroactive metabolites in response to inflammation. Delirium (acute confusion) is a common complication of acute illness and is associated with increased risk of dementia and mortality. However, the molecular mechanisms underlying delirium, particularly in relation to the KP, remain elusive. METHODS. We undertook a multicenter observational study with 586 hospitalized patients (248 with delirium) and investigated associations between delirium and KP metabolites measured in cerebrospinal fluid (CSF) and serum by targeted metabolomics. We also explored associations between KP metabolites and markers of neuronal damage and 1-year mortality. RESULTS. In delirium, we found concentrations of the neurotoxic metabolite quinolinic acid in CSF (CSF-QA) (OR 2.26 [1.78, 2.87], P < 0.001) to be increased and also found increases in several other KP metabolites in serum and CSF. In addition, CSF-QA was associated with the neuronal damage marker neurofilament light chain (NfL) (β 0.43, P < 0.001) and was a strong predictor of 1-year mortality (HR 4.35 [2.93, 6.45] for CSF-QA ≥ 100 nmol/L, P < 0.001). The associations between CSF-QA and delirium, neuronal damage, and mortality remained highly significant following adjustment for confounders and multiple comparisons. CONCLUSION. Our data identified how systemic inflammation, neurotoxicity, and delirium are strongly linked via the KP and should inform future delirium prevention and treatment clinical trials that target enzymes of the KP. FUNDING. Norwegian Health Association and South-Eastern Norway Regional Health Authorities.
- Open Access
- 9 April 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
Noradrenergic and dopaminergic neurons are involved in cognitive functions, relate to behavioral and psychological symptoms in dementia and are affected in Alzheimer’s disease (AD). Amyloid plaques (A), neurofibrillary tangles (T) and neurodegeneration (N) hallmarks the AD neuropathology. Today, the AT(N) pathophysiology can be assessed through biomarkers. Previous studies report cerebrospinal fluid (CSF) catecholamine concentrations in AD patients without biomarker refinement. We explored if CSF catecholamines relate to AD clinical presentation or neuropathology as reflected by CSF biomarkers. CSF catecholamines were analyzed in AD patients at the mild cognitive impairment (MCI; n = 54) or dementia stage (n = 240) and in cognitively unimpaired (n = 113). CSF biomarkers determined AT status and indicated synaptic damage (neurogranin). The AD patients (n = 294) had higher CSF noradrenaline and adrenaline concentrations, but lower dopamine concentrations compared to the cognitively unimpaired (n = 113). AD patients in the MCI and dementia stage of the disease had similar CSF catecholamine concentrations. In the CSF neurogranin positively associated with noradrenaline and adrenaline but not with dopamine. Adjusted regression analyses including AT status, CSF neurogranin, age, gender, and APOEε4 status verified the findings. In restricted analyses comparing A+T+ patients to A−T− cognitively unimpaired, the findings for CSF adrenaline remained significant (p < 0.001) but not for CSF noradrenaline (p = 0.07) and CSF dopamine (p = 0.33). There were no differences between A+T+ and A−T− cognitively unimpaired. Thus, we find alterations in CSF catecholamines in symptomatic AD and the CSF adrenergic transmitters to increase simultaneously with synaptic damage as indexed by CSF neurogranin.
- 9 April 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Open AccessCerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
Noradrenergic and dopaminergic neurons are involved in cognitive functions, relate to behavioral and psychological symptoms in dementia and are affected in Alzheimer’s disease (AD). Amyloid plaques (A), neurofibrillary tangles (T) and neurodegeneration (N) hallmarks the AD neuropathology. Today, the AT(N) pathophysiology can be assessed through biomarkers. Previous studies report cerebrospinal fluid (CSF) catecholamine concentrations in AD patients without biomarker refinement. We explored if CSF catecholamines relate to AD clinical presentation or neuropathology as reflected by CSF biomarkers. CSF catecholamines were analyzed in AD patients at the mild cognitive impairment (MCI; n = 54) or dementia stage (n = 240) and in cognitively unimpaired (n = 113). CSF biomarkers determined AT status and indicated synaptic damage (neurogranin). The AD patients (n = 294) had higher CSF noradrenaline and adrenaline concentrations, but lower dopamine concentrations compared to the cognitively unimpaired (n = 113). AD patients in the MCI and dementia stage of the disease had similar CSF catecholamine concentrations. In the CSF neurogranin positively associated with noradrenaline and adrenaline but not with dopamine. Adjusted regression analyses including AT status, CSF neurogranin, age, gender, and APOEε4 status verified the findings. In restricted analyses comparing A+T+ patients to A−T− cognitively unimpaired, the findings for CSF adrenaline remained significant (p < 0.001) but not for CSF noradrenaline (p = 0.07) and CSF dopamine (p = 0.33). There were no differences between A+T+ and A−T− cognitively unimpaired. Thus, we find alterations in CSF catecholamines in symptomatic AD and the CSF adrenergic transmitters to increase simultaneously with synaptic damage as indexed by CSF neurogranin.
- 28 March 2022
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 51 (1) , 80-89
Hippocampal Atrophy Subtypes of Alzheimer’s Disease Using Automatic MRI in a Memory Clinic Cohort: Clinical Implications
Introduction: One pathological hallmark of Alzheimer’s disease (AD) is atrophy of medial temporal brain regions that can be visualized on magnetic resonance imaging (MRI), but not all patients will have atrophy. The aim was to use MRI to categorize patients according to their hippocampal atrophy status and to present prevalence of the subtypes, difference in clinical symptomatology and progression, and factors associated with hippocampal subtypes. Methods: We included 215 patients with AD who had been assessed with the clinically available MRI software NeuroQuant (NQ; CorTechs labs/University of California, San Diego, CA, USA). NQ measures the hippocampus volume and calculates a normative percentile. Atrophy was regarded to be present if the percentile was ≤5. Demographics, cognitive measurements, AD phenotypes, apolipoprotein E status, and results from cerebrospinal fluid and amyloid positron emission tomography analyses were included as explanatory variables of the hippocampal subtypes. Results: Of all, 60% had no hippocampal atrophy. These patients were younger and less cognitively impaired concerning global measures, memory function, and abstraction but impaired concerning executive, visuospatial, and semantic fluency, and more of them had nonamnestic AD, compared to those with hippocampal atrophy. No difference in progression rate was observed between the two groups. In mild cognitive impairment patients, amyloid pathology was associated with the no hippocampal atrophy group. Conclusion: The results have clinical implications. Clinicians should be aware of the large proportion of AD patients presenting without atrophy of the hippocampus as measured with this clinical MRI method in the diagnostic set up and that nonamnestic phenotypes are more common in this group as compared to those with atrophy. Furthermore, the findings are relevant in clinical trials.
- 28 March 2022
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 51 (1) , 80-89
Hippocampal Atrophy Subtypes of Alzheimer’s Disease Using Automatic MRI in a Memory Clinic Cohort: Clinical Implications
Introduction: One pathological hallmark of Alzheimer’s disease (AD) is atrophy of medial temporal brain regions that can be visualized on magnetic resonance imaging (MRI), but not all patients will have atrophy. The aim was to use MRI to categorize patients according to their hippocampal atrophy status and to present prevalence of the subtypes, difference in clinical symptomatology and progression, and factors associated with hippocampal subtypes. Methods: We included 215 patients with AD who had been assessed with the clinically available MRI software NeuroQuant (NQ; CorTechs labs/University of California, San Diego, CA, USA). NQ measures the hippocampus volume and calculates a normative percentile. Atrophy was regarded to be present if the percentile was ≤5. Demographics, cognitive measurements, AD phenotypes, apolipoprotein E status, and results from cerebrospinal fluid and amyloid positron emission tomography analyses were included as explanatory variables of the hippocampal subtypes. Results: Of all, 60% had no hippocampal atrophy. These patients were younger and less cognitively impaired concerning global measures, memory function, and abstraction but impaired concerning executive, visuospatial, and semantic fluency, and more of them had nonamnestic AD, compared to those with hippocampal atrophy. No difference in progression rate was observed between the two groups. In mild cognitive impairment patients, amyloid pathology was associated with the no hippocampal atrophy group. Conclusion: The results have clinical implications. Clinicians should be aware of the large proportion of AD patients presenting without atrophy of the hippocampus as measured with this clinical MRI method in the diagnostic set up and that nonamnestic phenotypes are more common in this group as compared to those with atrophy. Furthermore, the findings are relevant in clinical trials.
- Open Access
- 4 January 2022
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 85 (1) , 197-205
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
Background: Patients with Alzheimer’s disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from 18F-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information. Objective: We investigate whether 18F-Flutemetamol PET composite or regional SUVRs are associated with trajectories of clinical progression. Methods: This observational longitudinal study included 94 patients with clinical AD. PET images were semi-quantified with normalization to pons. Group-based trajectory modeling was applied to identify trajectory groups according to change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) over time. Multinomial logistic regression models assessed the association of SUVRs with trajectory group membership. Results: Three trajectory groups were identified. In the regression models, neither composite nor regional SUVRs were associated with trajectory group membership. Conclusion: There were no associations between CDR progression and 18F-Flutemetamol PET-derived composite SUVRs or regional SUVRs in clinical AD.
- 4 January 2022
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 85 (1) , 197-205
Open AccessIs Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
Background: Patients with Alzheimer’s disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from 18F-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information. Objective: We investigate whether 18F-Flutemetamol PET composite or regional SUVRs are associated with trajectories of clinical progression. Methods: This observational longitudinal study included 94 patients with clinical AD. PET images were semi-quantified with normalization to pons. Group-based trajectory modeling was applied to identify trajectory groups according to change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) over time. Multinomial logistic regression models assessed the association of SUVRs with trajectory group membership. Results: Three trajectory groups were identified. In the regression models, neither composite nor regional SUVRs were associated with trajectory group membership. Conclusion: There were no associations between CDR progression and 18F-Flutemetamol PET-derived composite SUVRs or regional SUVRs in clinical AD.
- Open Access
- 16 August 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-9
Investigating novel biomarkers of immune activation and modulation in the context of sedentary behaviour: a multicentre prospective ischemic stroke cohort study
Background: Sedentary behaviour is associated with disease, but the molecular mechanisms are not understood. Valid biomarkers with predictive and explanatory properties are required. Therefore, we have investigated traditional and novel biomarkers of inflammation and immune modulation and their association to objectively measured sedentary behaviour in an ischemic stroke population. Methods: Patients admitted to hospital with acute ischemic stroke were included in the multicentre Norwegian Cognitive Impairment After Stroke (Nor-COAST) study (n = 815). For this sub-study (n = 257), sedentary behaviour was registered 3 months after stroke using position transition data from the body-worn sensor, ActivPal®. Blood samples were analysed for high sensitive C-reactive protein (hsCRP), the cytokines interleukin-6 (IL-6) and 10 (IL-10), neopterin, tryptophan (Trp), kynurenine (kyn), kynurenic acid (KA), and three B6 vitamers, pyridoxal 5′-phosphate (PLP), pyridoxal (PL), and pyridoxic acid (PA). The kynurenine/tryptophan ratio (KTR) and the pyridoxic acid ratio index (PAr = PA: PL + PLP) were calculated. Results: Of the 815 patients included in the main study, 700 attended the three-month follow-up, and 257 fulfilled the inclusion criteria for this study. Sedentary time was significantly associated with levels of hsCRP, IL-6, neopterin, PAr-index, and KA adjusted for age, sex, waist circumference, and creatinine. In a fully adjusted model including all the significant biomarkers except hsCRP (because of missing values), sedentary time was independently positively associated with the PAr-index and negatively with KA. We did not find an association between sedentary behaviour, IL-10, and KTR. Conclusions: The PAr-index is known to capture several modes of inflammation and has previously shown predictive abilities for future stroke. This novel result indicates that the PAr-index could be a useful biomarker in future studies on sedentary behaviour and disease progression. KA is an important modulator of inflammation, and this finding opens new and exciting pathways to understand the hazards of sedentary behaviour. Trial registration: The study was registered at Clinicaltrials.gov (NCT02650531). First posted 08/01/2016.
- 16 August 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-9
Open AccessInvestigating novel biomarkers of immune activation and modulation in the context of sedentary behaviour: a multicentre prospective ischemic stroke cohort study
Background: Sedentary behaviour is associated with disease, but the molecular mechanisms are not understood. Valid biomarkers with predictive and explanatory properties are required. Therefore, we have investigated traditional and novel biomarkers of inflammation and immune modulation and their association to objectively measured sedentary behaviour in an ischemic stroke population. Methods: Patients admitted to hospital with acute ischemic stroke were included in the multicentre Norwegian Cognitive Impairment After Stroke (Nor-COAST) study (n = 815). For this sub-study (n = 257), sedentary behaviour was registered 3 months after stroke using position transition data from the body-worn sensor, ActivPal®. Blood samples were analysed for high sensitive C-reactive protein (hsCRP), the cytokines interleukin-6 (IL-6) and 10 (IL-10), neopterin, tryptophan (Trp), kynurenine (kyn), kynurenic acid (KA), and three B6 vitamers, pyridoxal 5′-phosphate (PLP), pyridoxal (PL), and pyridoxic acid (PA). The kynurenine/tryptophan ratio (KTR) and the pyridoxic acid ratio index (PAr = PA: PL + PLP) were calculated. Results: Of the 815 patients included in the main study, 700 attended the three-month follow-up, and 257 fulfilled the inclusion criteria for this study. Sedentary time was significantly associated with levels of hsCRP, IL-6, neopterin, PAr-index, and KA adjusted for age, sex, waist circumference, and creatinine. In a fully adjusted model including all the significant biomarkers except hsCRP (because of missing values), sedentary time was independently positively associated with the PAr-index and negatively with KA. We did not find an association between sedentary behaviour, IL-10, and KTR. Conclusions: The PAr-index is known to capture several modes of inflammation and has previously shown predictive abilities for future stroke. This novel result indicates that the PAr-index could be a useful biomarker in future studies on sedentary behaviour and disease progression. KA is an important modulator of inflammation, and this finding opens new and exciting pathways to understand the hazards of sedentary behaviour. Trial registration: The study was registered at Clinicaltrials.gov (NCT02650531). First posted 08/01/2016.
- 1 August 2021
- Published by Elsevier in Atherosclerosis
- Vol. 331, e86
Sedentary behaviour and the immune system: Investigating traditional and novel biomarkers in a stroke population.
- 1 August 2021
- Published by Elsevier in Atherosclerosis
- Vol. 331, e86
Sedentary behaviour and the immune system: Investigating traditional and novel biomarkers in a stroke population.